

An AACR Special Conference in Cancer Research

# Bladder Cancer: Transforming the Field

May 17-20, 2024 | Le Meridien Charlotte | Charlotte, NC

**CURRENT AS OF 5/14/24**

**Conference Cochairs:**

Dan Theodorescu, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, CA

Donna E. Hansel, The University of Texas MD Anderson Cancer Center, Houston, TX

Tahlita Zuiverloon, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

Lars Dyrskjød, Department of Molecular Medicine, Aarhus University Hospital, Denmark

**FRIDAY, MAY 17**

---

**Registration**

4:00 pm-8:00 pm | Carolina Foyer

**Welcome and Introduction**

6:30 pm-6:40 pm | Carolina AC

*Not-CME eligible*

Dan Theodorescu, Cedars-Sinai Medical Center, Los Angeles, CA

Tahlita Zuiverloon, Erasmus MC Cancer Institute, Rotterdam,  
Netherlands

Lars Dyrskjød, Department of Molecular Medicine, Aarhus University  
Hospital, Denmark

**Opening Keynote Address**

6:40 pm-7:30 pm | Carolina AC

*CME eligible*

6:40- 6:45 p.m.

Introduction of Keynote Speaker

Dan Theodorescu, Cedars-Sinai Medical Center, Los Angeles, CA

6:45- 7:30 p.m.

**Cellular and molecular underpinnings of field cancerization and  
progression to invasive carcinoma in bladder cancer**

Philip A. Beachy, Stanford University, Stanford, CA

**Opening Reception**

7:30 pm-9:00 pm | Symphony I

An AACR Special Conference in Cancer Research

# Bladder Cancer: Transforming the Field

May 17-20, 2024 | Le Meridien Charlotte | Charlotte, NC

## SATURDAY, MAY 18

---

### Continental Breakfast

7:00 am-8:00 am | Mecklenberg

### Plenary Session 1: Tumor subtypes in 2024 and beyond – biological framework and potential clinical impact

8:00 am-9:30 am | Carolina AC

*Session Chair and Moderator: Lars Dyrskjød (Aarhus University)*

*CME eligible*

- |                 |  |
|-----------------|--|
| 8:00- 8:20 p.m. | <b>Dare to be different - understanding subtypes and divergence in urothelial carcinoma</b><br>Sara E. Wobker, University of North Carolina Chapel Hill, Charlotte, NC |
| 8:20-8:40 p.m.  | <b>Molecular subtypes of NMIBC</b><br>Sia V. Lindskrog, Aarhus University Hospital, Aarhus, Denmark  |
| 8:40-9:00 p.m.  | <b>Molecular subtypes and clinical benefit from neoadjuvant chemotherapy: A ten-year update</b><br>David J. McConkey, Johns Hopkins University, Baltimore, MD          |
| 9:00-9:30 p.m.  | Panel Discussion: Drs. Dyrskjød, Lindskrog, Wobker and McConkey  |

### Break

9:30 am-10:00 am | Carolina Foyer

### Plenary Session 2: Liquid biopsies for guiding treatment decisions

10:00 am-11:30 am | Carolina AC

*Session Chair: Philip Abbosh (Fox Chase)*

*CME eligible*

- |                 |  |
|-----------------|--|
| 10:00 -10:30 am | <b>Urine based liquid biopsy for the diagnosis, assessment, and staging of bladder cancer</b><br>Philip H. Abbosh, Fox Chase Cancer Center, Philadelphia, PA |
| 10:30 -11:00 am | <b>Circulating biomarkers in bladder cancer: can we predict relapse</b><br>Peter Kuhn, University of Southern California, Los Angeles, California            |
| 11:00 -11:30 am | <b>Towards ctDNA-guided treatment of muscle-invasive bladder cancer</b><br>Lars Dyrskjød, Aarhus University Hospital, Aarhus, Denmark                        |

An AACR Special Conference in Cancer Research

# Bladder Cancer: Transforming the Field

May 17-20, 2024 | Le Meridien Charlotte | Charlotte, NC

## Lunch on own

11:30 pm-1:30 pm

## Plenary Session 3: Sex, Hormone and stromal interactions in tumor growth and progression

1:30 pm-3:00 pm | Carolina AC

*Session Chair: Zihai Li (Ohio State)*

*CME eligible*

1:30 -2:00 pm	<b>Sex-based disparities in urothelial carcinoma: pathology and diagnosis</b> Donna E. Hansel, The University of Texas MD Anderson Cancer Center, Houston, TX
2:00 -2:30 pm	<b>Y chromosome loss in cancer drives growth by evasion of adaptive immunity</b> Dan Theodorescu, Cedars-Sinai Medical Center, Los Angeles, CA
2:30 -3:00 pm	<b>Immunological basis of sex bias and therapeutic opportunities in bladder cancer</b> Zihai Li, Ohio State University, Columbus, OH

## Break

3:00 pm-3:15 pm | Carolina Foyer

## Proffered Talks \*

*Session Chair: Donna Hansel (MD Anderson)*

3:15 pm-4:00 pm | Carolina AC

*CME eligible*

3:15 -3:30 pm	<b>Exploring the functional consequences of APOBEC3-induced non-coding hotspot mutations in bladder cancer using massively parallel reporter assays and CRISPR-mediated base editing.*</b> Rouf Banday, National Cancer Institute, Rockville, MD
3:30 -3:45 pm	<b>TRIM29 is required for basal bladder cancer invasive progression*</b> Alan Kelleher, University of Michigan, Ann Arbor, MI
3:45 -4:00 pm	<b>Sarcomatoid histological variants of canine muscle-invasive bladder cancer: transcription factor activation highlights pathways of epithelial-mesenchymal transformation similar to humans*</b> Karin Allenspach, University of Georgia, Athens, GA

An AACR Special Conference in Cancer Research

# Bladder Cancer: Transforming the Field

May 17-20, 2024 | Le Meridien Charlotte | Charlotte, NC

## Lightning talks Session I

*Session Chair: Donna Hansel (MD Anderson)*

4:00 pm-4:15 pm | Carolina AC

*CME eligible*

- |               |   |
|---------------|---|
| 4:05 -4:07 pm | <b>Integrative drug screening and multi-omic characterization of patient-derived bladder cancer organoids reveals novel molecular correlates of chemotherapy response</b><br>Nathan Merrill, University of Michigan, Ann Arbor, MI          |
| 4:09 -4:11 pm | <b>Racial differences in characteristics and outcomes of adjuvant nivolumab for muscle-invasive urothelial carcinoma (MIUC) in the real-world setting</b><br>Regina Barragan-Carrillo, City of Hope Comprehensive Cancer Center, Duarte, CA |

## Poster Session A / Reception

4:15 pm-6:15 pm | Mecklenberg

*Not-CME eligible*

## SUNDAY, MAY 19

---

### Continental Breakfast

7:00 am-8:00 am | Mecklenberg

### Plenary Session 4: Immune cell context and treatment responses

8:00 am-10:00 am | Carolina AC

*Session Chair: Dan Theodorescu (Ceders-Sinai)*

*CME eligible*

- |               |   |
|---------------|---|
| 8:00 -8:30 am | <b>Tumor HLA-E expression and cytomegalovirus infection modulate NK cell activity in human bladder cancer</b><br>Amir Horowitz, Icahn School of Medicine at Mount Sinai, New York, NY                             |
| 8:30 -8:45 am | <b>Spatial proteomics and transcriptomics reveal an altered immune cell landscape in bladder cancer patients unresponsive to BCG treatment*</b><br>Trine Strandgaard, Aarhus University Hospital, Aarhus, Denmark |

An AACR Special Conference in Cancer Research

# Bladder Cancer: Transforming the Field

May 17-20, 2024 | Le Meridien Charlotte | Charlotte, NC

- |                |  |
|----------------|--|
| 8:45 -9:15 am  | <b>Dissecting innate immune mechanisms of resistance to immune checkpoint blockade therapy in bladder cancer [R]</b><br>Nina Bhardwaj, Icahn School of Medicine at Mount Sinai, New York, NY |
| 9:15 -9:30 am  | <b>T cell receptor repertoire and diversity are prognostic markers in bladder cancer*</b><br>Nanna Kristjánsdóttir, Aarhus University, Aarhus, Denmark                                       |
| 9:30 -10:00 am | <b>Immune cell context in BCG-treated patients</b><br>Tahlita Zuiverloon, Erasmus MC Cancer Institute, Rotterdam, The Netherlands  |

## Break

10:00 am-10:30 am | Carolina Foyer

## Plenary Session 5: Novel approaches for managing non-invasive disease

10:30 am-12:30 pm | Carolina AC

*Session Chair: Ashish Kamat (MD Anderson)*

*CME eligible*

- |                 |  |
|-----------------|--|
| 10:30 -11:00 am | <b>Setting the stage for trials in NMIBC</b><br>Ashish M. Kamat, The University of Texas MD Anderson Cancer Center, Houston, TX  |
| 11:00 -11:15 am | <b>EG-70 (detalimogene voraplasamid), a novel, non-viral intravesical gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: preclinical characterization and translation into the clinic*</b><br>James Sullivan, enGene Inc, Boston, MA                          |
| 11:15 -11:45 am | <b>Conditional reprogramming modeling of bladder cancer for clinical translation</b><br>Cheryl T. Lee, The Ohio State University, Columbus, OH   |
| 11:45 -12:00 pm | <b>Final results from a Phase I trial of intravesical chemoimmunotherapy with gemcitabine and Bacillus Calmette-Guérin (BCG) for patients with BCG-exposed high-grade non-muscle invasive bladder cancer*</b><br>Syed Alam, Memorial Sloan Kettering Cancer Center, New York, NY |
| 12:00 -12:30 pm | <b>The evolution of multi-disciplinary care for non-muscle invasive bladder cancer patients</b><br>Noah M. Hahn, Johns Hopkins University, Baltimore, MD   |

An AACR Special Conference in Cancer Research

# Bladder Cancer: Transforming the Field

May 17-20, 2024 | Le Meridien Charlotte | Charlotte, NC

## Lunch on Own

12:30 pm-2:00 pm

## Plenary Session 6: Novel approaches for managing invasive disease

2:00 pm-4:00 pm | Carolina AC

*Session Chair: Tahlita Zuiverloon*

*CME eligible*

2:00 -2:30 pm	<b>Current state of the art: Bladder-preserving trimodality therapy for muscle-invasive bladder cancer</b> Jason A. Efstathiou, Massachusetts General Hospital, Boston, MA
2:30 -2:45 pm	<b>Modulating the PPAR<math>\gamma</math> pathway to augment NECTIN4-targeting chimeric antigen receptor (CAR) T cell therapy*</b> Jonathan Chou, University of California San Francisco, San Francisco, CA
2:45 -3:15 pm	<b>Defining the actionable genome</b> David B. Solit, Memorial Sloan Kettering Cancer Center, New York, NY
3:15 -3:45 pm	<b>Optimizing cystectomy outcomes in MIBC: What's new in 2024?</b> Jeremy Teoh, The Chinese University of Hong Kong, Hong Kong
3:45 -4:00 pm	<b>Identifying targeted therapies for muscle invasive bladder cancer via STAG2 expression*</b> Sarah Athans, Roswell Park Comprehensive Cancer Center, Buffalo, NY

## Lightning Talk Session II

4:00 pm-4:05 pm | Carolina AC

*Session Chair: Tahlita Zuiverloon*

*CME eligible*

4:03 -4:05 pm	<b>Novel mesothelin-based CAR T cells targeting MUC16 as an intravesical bladder cancer therapy</b> Parwiz Abrahimi, Weil Cornell Medicine, New York, NY
---------------	---

## Poster Session B/ Reception

4:15 pm-6:15 pm | Mecklenberg

*Not-CME eligible*

An AACR Special Conference in Cancer Research

# Bladder Cancer: Transforming the Field

May 17-20, 2024 | Le Meridien Charlotte | Charlotte, NC

## MONDAY, MAY 20

---

### Continental Breakfast

7:00 am-8:00 am | Mecklenberg

### Plenary Session 7: Management and treatment of metastatic disease

8:00 am-9:30 am | Carolina AC

*Session Chair: Nicholas Simon (NCI)*

*CME eligible*

8:00 -8:30 am	<b>The evolving role of immune-based treatment strategies in metastatic urothelial cancer</b> Matthew Galsky, Icahn School of Medicine at Mount Sinai, New York, NY
8:30 -9:00 am	<b>The interplay between mutagenesis and extrachromosomal DNA shapes urothelial cancer evolution</b> Bishoy M. Faltas, Weill Cornell Medicine, New York, NY
9:00 -9:30 am	<b>Metastatic bladder cancer: The expanding role of antibody drug conjugates</b> Nicholas Simon, National Institutes of Health, Bethesda, MD

### Break

9:30-9:45 am | Carolina Foyer

### Closing Keynote Address

9:45 am-10:30 am | Carolina AC

*CME eligible*

9:45 -9:47 am	Introduction of Keynote Speaker Lars Dyrskjød, Aarhus University Hospital, Denmark <i>Not-CME eligible</i>
9:47 -10:30 am	<b>Lessons from glioblastoma diversity, heterogeneity, and beginnings</b> Luis F. Parada, Memorial Sloan Kettering Cancer Center, New York, New York

An AACR Special Conference in Cancer Research

## Bladder Cancer: Transforming the Field

May 17-20, 2024 | Le Meridien Charlotte | Charlotte, NC

### Plenary Session 8: Future of Artificial Intelligence in bladder cancer research and patient management

10:30 am-12:30 pm | Carolina AC

*Session Chair: Joshua J. Levy (Ceders-Sinai)*

*CME eligible*

10:30 -11:00 am	<b>AI-powered tool for rapid reliable bladder cancer screening and surveillance: multicenter validation efforts</b> Joshua J. Levy, Cedars Sinai Medical Center, Los Angeles, CA
11:00 -11:15 am	<b>Exploratory analysis of tumor tertiary lymphoid structures using a novel artificial intelligence–based approach in patients with muscle-invasive urothelial carcinoma from the CheckMate 274 trial*</b> Matthew Milowsky, University of North Carolina at Chapel Hill, Chapel Hill, NC
11:15 -11:15 am	<b>AI-driven multimodal computational pathology</b> Faisal Mahmood, Harvard Medical School, Boston, MA
11:45 -12:00 pm	<b>Imaging mass cytometry captures patient heterogeneity enabling BCG response stratification in non-muscle invasive bladder cancer*</b> Ali Foroughi Pour, The Jackson Laboratory for Genomic Medicine, Farmington, CT
12:00 -12:30 pm	<b>AI in bladder cancer pathology and research: What can we expect and what not?</b> Markus Eckstein, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

### Closing Remarks | Carolina AC

12:30 p.m.